These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30635421)

  • 1. Crystal structure of the WD40 domain dimer of LRRK2.
    Zhang P; Fan Y; Ru H; Wang L; Magupalli VG; Taylor SS; Alessi DR; Wu H
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1579-1584. PubMed ID: 30635421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Parkinson's disease-related mutations disrupt the dimerization of WD40 domain in LRRK2: a comparative molecular dynamics simulation study.
    Li X; Ye M; Wang Y; Qiu M; Fu T; Zhang J; Zhou B; Lu S
    Phys Chem Chem Phys; 2020 Sep; 22(36):20421-20433. PubMed ID: 32914822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.
    Guaitoli G; Raimondi F; Gilsbach BK; Gómez-Llorente Y; Deyaert E; Renzi F; Li X; Schaffner A; Jagtap PK; Boldt K; von Zweydorf F; Gotthardt K; Lorimer DD; Yue Z; Burgin A; Janjic N; Sattler M; Versées W; Ueffing M; Ubarretxena-Belandia I; Kortholt A; Gloeckner CJ
    Proc Natl Acad Sci U S A; 2016 Jul; 113(30):E4357-66. PubMed ID: 27357661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Roc-COR tandem domain of leucine-rich repeat kinase 2 forms dimers and exhibits conventional Ras-like GTPase properties.
    Mills RD; Liang LY; Lio DS; Mok YF; Mulhern TD; Cao G; Griffin M; Kenche VB; Culvenor JG; Cheng HC
    J Neurochem; 2018 Nov; 147(3):409-428. PubMed ID: 30091236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2.
    Dederer V; Sanz Murillo M; Karasmanis EP; Hatch KS; Chatterjee D; Preuss F; Abdul Azeez KR; Nguyen LV; Galicia C; Dreier B; Plückthun A; Versees W; Mathea S; Leschziner AE; Reck-Peterson SL; Knapp S
    J Biol Chem; 2024 Jul; 300(7):107469. PubMed ID: 38876305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
    Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE
    Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the Influence of Specific Splicing Events on the Structural Organization of
    Vlachakis D; Labrou NE; Iliopoulos C; Hardy J; Lewis PA; Rideout H; Trabzuni D
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2.
    Huang X; Wu C; Park Y; Long X; Hoang QQ; Liao J
    FASEB J; 2019 Apr; 33(4):4814-4823. PubMed ID: 30592623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain.
    Piccoli G; Onofri F; Cirnaru MD; Kaiser CJ; Jagtap P; Kastenmüller A; Pischedda F; Marte A; von Zweydorf F; Vogt A; Giesert F; Pan L; Antonucci F; Kiel C; Zhang M; Weinkauf S; Sattler M; Sala C; Matteoli M; Ueffing M; Gloeckner CJ
    Mol Cell Biol; 2014 Jun; 34(12):2147-61. PubMed ID: 24687852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.
    Jaleel M; Nichols RJ; Deak M; Campbell DG; Gillardon F; Knebel A; Alessi DR
    Biochem J; 2007 Jul; 405(2):307-17. PubMed ID: 17447891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Markov State Models and Molecular Dynamics Simulations Provide Understanding of the Nucleotide-Dependent Dimerization-Based Activation of LRRK2 ROC Domain.
    Li X; Qi Z; Ni D; Lu S; Chen L; Chen X
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.
    Deng J; Lewis PA; Greggio E; Sluch E; Beilina A; Cookson MR
    Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1499-504. PubMed ID: 18230735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric inhibition of LRRK2, where are we now.
    Soliman A; Cankara FN; Kortholt A
    Biochem Soc Trans; 2020 Oct; 48(5):2185-2194. PubMed ID: 33079169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.
    Park Y; Liao J; Hoang QQ
    Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
    Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
    Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
    Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
    Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization.
    Pathak P; Alexander KK; Helton LG; Kentros M; LeClair TJ; Zhang X; Ho FY; Moore TT; Hall S; Guaitoli G; Gloeckner CJ; Kortholt A; Rideout H; Kennedy EJ
    ACS Chem Neurosci; 2023 Jun; 14(11):1971-1980. PubMed ID: 37200505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.